Aging
Featured Topics
Lead story
Other featured articles
-
NAM Expert Briefing on Behavioral and Social Science Research Questions Raised By the Use of Biomarkers for Alzheimer’s Disease Diagnostics
On June 28 and 29, 2021, the National Academies of Sciences, Engineering, and Medicine convened an expert meeting that addressed behavioral and social science research questions raised by the use of biomarkers and other measures for pre-clinical AD/ADRD diagnosis
-
NAS Report Outlines Priorities for the Next Ten Years of Alzheimer’s Research
Julie Zissimopoulos participated on the committee tasked with developing the research agenda.
Posted in -
Advancing the Economics of Palliative Care: The Value to Individuals and Families, Organizations, and Society
A palliative care research agenda can help lay the foundation for building a strong evidence base to guide public policies meant to advance affordable, equitable, high-quality, patient-centered care.
Posted in -
Leveraging Behavioral Sciences for Dementia Care
Insights from the behavioral sciences may help doctors detect dementia earlier and develop more insightful care plans.
Posted in
About this section
People are living longer, which brings obvious benefits as well as considerable challenges — from Alzheimer’s and other age-related diseases to increased injuries, disabilities and poverty risks. Policymakers around the world rely on Schaeffer Center research and modeling tools for finding ways to help keep people as healthy as possible throughout their lives.
Our Experts On Aging
Our Work In Aging
-
Disparate Aging: The Role of Education and Socioeconomic Gradients in Future Health and Disability in an International Context
If on one side ageing is driven by biological changes, on the other side the ageing itself reflects the accumulated effects of one’s exposure to a history of external risks, and can further be influenced by social changes, such as isolation and loss of loved ones.
Categorized in -
FDA’s Approval of Aducanumab Paves the Way for ‘More Momentous’ Alzheimer’s Breakthroughs
The FDA’s recent approval of the first disease-modifying therapy for Alzheimer’s will fuel the chances of even more breakthroughs.
-
Applying for the 2022-2023 Roybal Center for Behavioral Interventions in Aging Pilot Projects
The Roybal Center for Behavioral Interventions in Aging seeks proposals for pilot projects that involve randomized controlled trials (RCTs).
-
Examining Primary Care Physician Rationale for not Following Geriatric Choosing Wisely Recommendations
Why do physicians order tests or treatments in older adults contrary to published recommendations?
Categorized in -
Comparison of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Bioprosthetic Heart Valves
Use of direct oral anticoagulants gradually increased since 2011, with a significant upward in trend after a stay-at-home order related to COVID-19.
Categorized in -
Podcast: The Impact and Economics of Alzheimer’s
Julie Zissimopoulos recently spoke about her research using economic insights to better understand the impact of Alzheimer’s disease on individuals, families, caregivers, and society.